{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:27:05Z","timestamp":1789669625249,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11845-022-03066-y","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T02:02:31Z","timestamp":1655517751000},"page":"633-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term follow-up of treatment-na\u00efve HBeAg-negative patients with chronic hepatitis B"],"prefix":"10.1007","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-5091","authenticated-orcid":false,"given":"Yusuf Emre","family":"Ozdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-3840","authenticated-orcid":false,"given":"Meryem","family":"Sahin Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7311-3258","authenticated-orcid":false,"given":"Osman Faruk","family":"Bayramlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7239-1133","authenticated-orcid":false,"given":"Serkan","family":"Surme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6319-7889","authenticated-orcid":false,"given":"Sibel","family":"Yildiz Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2440-7529","authenticated-orcid":false,"given":"Ridvan","family":"Karaali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-5931","authenticated-orcid":false,"given":"Ilker Inanc","family":"Balkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-6087","authenticated-orcid":false,"given":"Bilgul","family":"Mete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4239-9585","authenticated-orcid":false,"given":"Nese","family":"Saltoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-2825","authenticated-orcid":false,"given":"Fehmi","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"issue":"10003","key":"3066_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT et al (2015) Estimations of worldwide prevalence of chronic hepatitis B virus \u0131nfection: a systematic review of data published between 1965 and 2013. The Lancet 386(10003):1546\u20131555. https:\/\/doi.org\/10.1016\/S0140-6736(15)61412-X","journal-title":"The Lancet"},{"issue":"9","key":"3066_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/MCG.0000000000000647","volume":"50","author":"J Feld","year":"2016","unstructured":"Feld J, Janssen HL, Abbas Z, Elewaut A et al (2016) World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. J Clin Gastroenterol 50(9):691\u2013703. https:\/\/doi.org\/10.1097\/MCG.0000000000000647","journal-title":"J Clin Gastroenterol"},{"key":"3066_CR3","unstructured":"Agca H (2015) Hepatitis B virus serology. In: Altindis M, Tabak F (eds) Hepatitis microbiology. Istanbul Tip Kitabevi, Istanbul, pp 76\u201382"},{"key":"3066_CR4","unstructured":"Ozacar T, Say\u0131ner A (2017) Hepatitis B virus. In: Topcu AW, Soyletir G, Doganay M (eds) Infectious diseases and microbiology, 4th ed. Nobel T\u0131p Kitabevleri, Istanbul, pp 1670\u201386"},{"issue":"1","key":"3066_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clinre.2017.06.008","volume":"42","author":"B Kayaaslan","year":"2018","unstructured":"Kayaaslan B, Akinci E, Ari A et al (2018) A long-term multicenter study: entecavir versus tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol 42(1):40\u201347. https:\/\/doi.org\/10.1016\/j.clinre.2017.06.008","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"3066_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"Liver EAfTSoT.","year":"2017","unstructured":"Liver EAfTSoT. (2017) EASL 2017 Clinical practice guidelines on the management of hepatitis B virus \u0131nfection. J Hepatol 67(2):370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"3066_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696\u2013699. https:\/\/doi.org\/10.1016\/0168-8278(95)80226-6","journal-title":"J Hepatol"},{"issue":"2","key":"3066_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"Liver EAfTSoT.","year":"2018","unstructured":"Liver EAfTSoT. (2018) EASL Clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69(2):406\u2013460. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024","journal-title":"J Hepatol"},{"issue":"2","key":"3066_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4274\/vhd.galenos.2020.2019.0038","volume":"26","author":"S Sayar","year":"2020","unstructured":"Sayar S, Atalay R, Cakmak S et al (2020) Diagnostic performance of non-invasive fibrosis \u0131ndexes in hepatitis B related fibrosis. Viral Hepatitis Journal 26(2):78\u201384. https:\/\/doi.org\/10.4274\/vhd.galenos.2020.2019.0038","journal-title":"Viral Hepatitis Journal"},{"issue":"10","key":"3066_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"C-L Lai","year":"2006","unstructured":"Lai C-L, Shouval D, Lok AS et al (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354(10):1011\u20131020. https:\/\/doi.org\/10.1056\/NEJMoa051287","journal-title":"N Engl J Med"},{"key":"3066_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/liv.13641","volume":"38","author":"M Buti","year":"2018","unstructured":"Buti M, Riveiro-Barciela M, Esteban R (2018) Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int 38:84\u201389. https:\/\/doi.org\/10.1111\/liv.13641","journal-title":"Liver Int"},{"key":"3066_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijid.2014.09.004","volume":"28","author":"A Batirel","year":"2014","unstructured":"Batirel A, Guclu E, Arslan F et al (2014) Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-na\u00efve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis 28:153\u2013159. https:\/\/doi.org\/10.1016\/j.ijid.2014.09.004","journal-title":"Int J Infect Dis"},{"issue":"25","key":"3066_CR13","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"C-L Lai","year":"2007","unstructured":"Lai C-L, Gane E, Liaw Y-F et al (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357(25):2576\u20132588. https:\/\/doi.org\/10.1056\/NEJMoa066422","journal-title":"N Engl J Med"},{"issue":"18","key":"3066_CR14","first-page":"2467","volume":"17","author":"B Ceylan","year":"2013","unstructured":"Ceylan B, Yardimci C, Fincanci M et al (2013) Comparison of tenofovir and entecavir in patients with chronic HBV \u0131nfection. Eur Rev Med Pharmacol Sci 17(18):2467\u20132473","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"43","key":"3066_CR15","doi-asserted-by":"publisher","first-page":"12421","DOI":"10.3748\/wjg.v21.i43.12421","volume":"21","author":"N Li","year":"2015","unstructured":"Li N, Xu J-H, Yu M et al (2015) Relationship between virological response and FIB-4 \u0131ndex in chronic hepatitis B patients with entecavir therapy. World J Gastroenterol 21(43):12421. https:\/\/doi.org\/10.3748\/wjg.v21.i43.12421","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3066_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ et al (2009) Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49(5):1503\u20131514. https:\/\/doi.org\/10.1002\/hep.22841","journal-title":"Hepatology"},{"issue":"9","key":"3066_CR17","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","volume":"48","author":"D Tenney","year":"2004","unstructured":"Tenney D, Levine S, Rose R et al (2004) Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48(9):3498\u20133507. https:\/\/doi.org\/10.1128\/AAC.48.9.3498-3507.2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3066_CR18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","volume":"70","author":"E-S Park","year":"2019","unstructured":"Park E-S, Lee AR, Kim DH et al (2019) Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol 70(6):1093\u20131102. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.006","journal-title":"J Hepatol"},{"key":"3066_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104548","volume":"129","author":"J Mokaya","year":"2020","unstructured":"Mokaya J, Maponga TG, McNaughton AL et al (2020) Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) \u0131nfection: an observational case series of South African adults. J Clin Virol 129:104548. https:\/\/doi.org\/10.1016\/j.jcv.2020.104548","journal-title":"J Clin Virol"},{"issue":"5","key":"3066_CR20","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","volume":"60","author":"M Buti","year":"2015","unstructured":"Buti M, Tsai N, Petersen J et al (2015) Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 60(5):1457\u20131464. https:\/\/doi.org\/10.1007\/s10620-014-3486-7","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3066_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-017-0596-7","volume":"17","author":"JW Park","year":"2017","unstructured":"Park JW, Kwak KM, Kim SE et al (2017) Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naive chronic hepatitis B patients. BMC Gastroenterol 17(1):1\u20139. https:\/\/doi.org\/10.1186\/s12876-017-0596-7","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"3066_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N et al (2009) 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136(2):486\u2013495. https:\/\/doi.org\/10.1053\/j.gastro.2008.10.026","journal-title":"Gastroenterology"},{"issue":"8","key":"3066_CR23","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/135965350701200816","volume":"12","author":"M Yuen","year":"2007","unstructured":"Yuen M, Seto W-K, Chow D et al (2007) Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B \u0131nfection even in patients without advanced disease. Antivir Ther 12(8):1295. https:\/\/doi.org\/10.1177\/135965350701200816","journal-title":"Antivir Ther"},{"issue":"18","key":"3066_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.21037\/atm.2016.09.19","volume":"4","author":"F Tacke","year":"2016","unstructured":"Tacke F, Kroy DC (2016) Treatment for hepatitis B in patients with drug resistance. Annals of Translational Medicine 4(18):334. https:\/\/doi.org\/10.21037\/atm.2016.09.19","journal-title":"Annals of Translational Medicine"},{"issue":"3","key":"3066_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.5152\/tjg.2016.16085","volume":"27","author":"K Atay","year":"2016","unstructured":"Atay K, Hatemi \u0130, Canbakan B et al (2016) Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B. Turk J Gastroenterol 27(3):279\u2013283. https:\/\/doi.org\/10.5152\/tjg.2016.16085","journal-title":"Turk J Gastroenterol"},{"key":"3066_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3350\/cmh.2016.0045","volume":"22","author":"I Varbobitis","year":"2016","unstructured":"Varbobitis I, Papatheodoridis GV (2016) The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol 22:319\u2013326. https:\/\/doi.org\/10.3350\/cmh.2016.0045","journal-title":"Clin Mol Hepatol"},{"issue":"40","key":"3066_CR27","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.3748\/wjg.v24.i40.4606","volume":"24","author":"YC Ju","year":"2018","unstructured":"Ju YC, Jun DW, Choi J et al (2018) Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis. World J Gastroenterol 24(40):4606\u20134614. https:\/\/doi.org\/10.3748\/wjg.v24.i40.4606","journal-title":"World J Gastroenterol"},{"issue":"2","key":"3066_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/apt.12344","volume":"38","author":"AK Singal","year":"2013","unstructured":"Singal AK, Salameh H, Kuo YF et al (2013) Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 38(2):98\u2013106. https:\/\/doi.org\/10.1111\/apt.12344","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03066-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03066-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03066-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T17:07:19Z","timestamp":1680455239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03066-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3066"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03066-y","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Clinical Research Ethics Committee (approval date: 01.10.2019, approval no: 83045809\u2013604.01.02). Written informed consent was waived, given the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}